Nicholas C Turner

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer
    Vikram K Jain
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:208. 2012
  2. pmc FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
  3. ncbi request reprint Basal-like breast cancer and the BRCA1 phenotype
    N C Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, UK
    Oncogene 25:5846-53. 2006
  4. doi request reprint A therapeutic target for smoking-associated lung cancer
    Nicholas C Turner
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Sci Transl Med 2:62ps56. 2010
  5. pmc FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
  6. pmc Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
    N Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:2013-23. 2010
  7. doi request reprint Fibroblast growth factor signalling: from development to cancer
    Nicholas Turner
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK, and Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 10:116-29. 2010
  8. pmc Management of breast cancer--Part II
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a540. 2008
  9. pmc Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
  10. pmc FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
    Rachel Sharpe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:5275-86. 2011

Collaborators

Detail Information

Publications23

  1. pmc Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer
    Vikram K Jain
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:208. 2012
    ..We discuss the multiple therapeutic strategies in preclinical and clinical development and the current and future challenges to successfully targeting this pathway in cancer...
  2. pmc FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
    ..Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line...
  3. ncbi request reprint Basal-like breast cancer and the BRCA1 phenotype
    N C Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, UK
    Oncogene 25:5846-53. 2006
    ..We review these phenotypes, the evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the clinical significance of the basal-like phenotype for cancer genetics and treatment...
  4. doi request reprint A therapeutic target for smoking-associated lung cancer
    Nicholas C Turner
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Sci Transl Med 2:62ps56. 2010
    ..This genetic variation may represent the first relatively high-frequency therapeutic target of smoking-associated lung cancer...
  5. pmc FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
    ..Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance...
  6. pmc Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
    N Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:2013-23. 2010
    ..0065). Our analysis demonstrates that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours...
  7. doi request reprint Fibroblast growth factor signalling: from development to cancer
    Nicholas Turner
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK, and Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 10:116-29. 2010
    ....
  8. pmc Management of breast cancer--Part II
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a540. 2008
  9. pmc Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
    ..In conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic targets in cancer...
  10. pmc FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
    Rachel Sharpe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:5275-86. 2011
    ..Substantial evidence now links aberrant signaling by the fibroblast growth factor receptors (FGFR) to the development of multiple cancer types. Here, we examined the role of FGFR signaling in TN breast cancer...
  11. doi request reprint Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1
    Marieke Aarts
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research Breast Unit, UK
    Cancer Discov 2:524-39. 2012
    ..These features are characteristic of aggressive breast, and other, cancers for which WEE1 inhibitor combinations represent a promising targeted therapy...
  12. doi request reprint A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    DNA Repair (Amst) 7:2010-9. 2008
    ..Furthermore, the identification of these novel determinants may eventually guide the optimal use of PARP inhibitors in the clinic...
  13. doi request reprint Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Cancer Cell 13:91-104. 2008
    ..The association of low levels of CDK10 with methylation of the CDK10 promoter suggests a mechanism by which CDK10 expression is reduced in tumors...
  14. ncbi request reprint FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  15. pmc A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
    Nicholas C Turner
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO J 27:1368-77. 2008
    ..These results highlight the potential of synthetic lethal siRNA screens with chemical inhibitors to define new determinants of sensitivity and potential therapeutic targets...
  16. doi request reprint Noninvasive detection of HER2 amplification with plasma DNA digital PCR
    Heidrun Gevensleben
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 19:3276-84. 2013
    ..We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and exemplify this approach by developing a plasma DNA digital PCR assay for HER2 copy number...
  17. pmc Functional viability profiles of breast cancer
    Rachel Brough
    The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom
    Cancer Discov 1:260-73. 2011
    ..We also show that large-scale functional profiling allows the classification of breast cancers into subgroups distinct from established subtypes...
  18. pmc A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
    Monika Graeser
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Academic Department of Biochemistry, and Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 16:6159-68. 2010
    ....
  19. pmc Management of breast cancer--part I
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a421. 2008
  20. pmc Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
    Maria Teresa Herrera-Abreu
    1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research 2Breast Unit, Royal Marsden Hospital, London 3Institute of Cancer Therapeutics, University of Bradford, Bradford and 4Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, United Kingdom
    Cancer Discov 3:1058-71. 2013
    ..Our results illustrate the power of parallel RNAi screens in identifying common resistance mechanisms to targeted therapies. ..
  21. doi request reprint Genetic heterogeneity and cancer drug resistance
    Nicholas C Turner
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lancet Oncol 13:e178-85. 2012
    ..Here, we describe the potential role of clonal heterogeneity in resistance to targeted therapy, discuss genetic instability as one of its causes, and detail approaches to tackle intra-tumour heterogeneity in the clinic...
  22. doi request reprint Tumour selective targeting of cell cycle kinases for cancer treatment
    Marieke Aarts
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Curr Opin Pharmacol 13:529-35. 2013
    ..TP53 mutant cancer cell lines are sensitive to WEE1 and CHK1 inhibitors in combination with chemotherapy, while PTEN-deficient aneuploid cancer cell lines are sensitive to TTK inhibitors. ..
  23. ncbi request reprint BRCA1 dysfunction in sporadic basal-like breast cancer
    N C Turner
    Chester Beatty Laboratories, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 26:2126-32. 2007
    ..0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer...